Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. - Wikidata - wikimedia - TriplyDB

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

http://www.wikidata.org/entity/Q34706690

about

Targeting device therapy: genomics of sudden death.Gene Variant of the Bradykinin B2 Receptor Influences Pulmonary Arterial Pressures in Heart Failure Patients.GENETIC VARIATION IN THE β(2)-ADRENERGIC RECEPTOR: IMPACT ON INTERMEDIATE CARDIOVASCULAR PHENOTYPES Adrenoreceptors and nitric oxide in the cardiovascular system.

P2860

Q33708542-1271A8F7-0664-453E-824D-25F27FF3B601 Q34201895-8E4ED053-B0B8-48DD-9546-12C47EB4952F Q37117267-A34E3970-E3D1-4E08-90C0-2DBFB78B06FF Q38162217-CDA54EB4-DA47-4CC1-9662-25DDBD87D840

P2860

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

http://www.wikidata.org/entity/Q34706690

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@ast

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@en

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@nl

type

label

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@ast

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@en

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@nl

prefLabel

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@ast

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@en

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@nl

P1433

Q34706690-FFA3D0D6-33D2-4E28-B1C9-D21E7D070236

P1476

Q34706690-3EF37E02-9B8A-4911-97F0-A9CAE6826B08

P2093

Q34706690-1B07E8C8-D7FC-4176-8B66-86124BDE9B9B

Q34706690-5CBD4345-5A59-4E28-969B-50595955ECBA

Q34706690-9FDD786A-CAF3-418A-977D-0118567FDC7E

P2860

Q34706690-038D41B5-1707-4DF7-9508-36F693DF6D20

Q34706690-1B64F1FF-C885-4DF1-BC2F-AFB63695ACE1

Q34706690-2CCF95CF-F30E-4173-BA7B-B26F31D5AF39

Q34706690-2DAB096F-4D75-47B4-86EB-F47A9086A853

Q34706690-302D08AD-C790-4F51-8A3E-A5E5D67E7021

Q34706690-5D96CC96-DFA0-4F32-BF6E-357289ED1FE2

Q34706690-928CDCED-7F64-4C41-8D52-35A035DBF4D9

Q34706690-BAEA2BDF-E45B-426A-A39F-F6630E7B6860

Q34706690-C5BA139E-A884-4817-9315-BD59AF79A9DB

Q34706690-D27EDE16-4D2D-436B-9A24-A6502501CC52

P2888

Q34706690-4F3B7CD4-5046-43A7-842F-52D3EF46725F

P304

Q34706690-D52DC255-23D3-4382-8D81-539E7A0857DA

P31

Q34706690-1715F090-086D-4EA0-8662-21272835D0B0

P356

Q34706690-0486BFE4-FE83-4E9A-9338-6E4DF586696B

P433

Q34706690-FAB8F6FC-FAF4-4000-B062-76616082FD79

P478

Q34706690-2DA89039-31F9-4CCB-86E7-27D3856EE77A

P577

Q34706690-088D7F25-2E32-48CC-8172-2A99F66836D6

P5875

Q34706690-100104BD-0A6B-4EE0-A36C-D2B240C77A46

P6179

Q34706690-57E4AF7B-2479-4AEA-94C1-E62319578C48

P698

Q34706690-72cdb5d2-8e24-417e-9443-590919ddf72f

Q34706690-E627D234-763C-42C4-903F-04D9AFE22050

P921

Q34706690-2277EA24-F6AF-4372-9301-757699646E49

P356

P1433

Molecular Diagnosis and Therapy

P1476

Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.

@en

P2093

Barry London

http://www.w3.org/2001/XMLSchema#string

Dennis M McNamara

http://www.w3.org/2001/XMLSchema#string

Guy A MacGowan

http://www.w3.org/2001/XMLSchema#string

P2860

A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor.

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.

Heparin-binding EGF-like growth factor: a juxtacrine growth factor.

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.

Seven-transmembrane-spanning receptors and heart function.

Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction

Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor.

P2888

P304

73-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500098

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11324733

http://www.w3.org/2001/XMLSchema#string

P6179

1038438600

http://www.w3.org/2001/XMLSchema#string

P698

12083943

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease